{
    "nctId": "NCT02555696",
    "briefTitle": "Abraxane in Treatment of Metastatic Breast Cancer",
    "officialTitle": "Assessment of Abraxane in Metastatic Breast Cancer in a Real-life Setting",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 203,
    "primaryOutcomeMeasure": "Adverse Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with metastatic breast cancer (according to European Summary of Product characteristics (SmPC)\n2. Signed Informed Consent\n3. Participants \\> 18 Years of Age\n\nExclusion Criteria:\n\n1. Pregnant or lactating females\n2. Neutrophils \\<1.5 X 10\\^9/L\n3. Hypersensivity to nab-paclitaxel",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}